Phenolphthalein linked to greater lymphoma incidence at high doses in mice -- NTP.
This article was originally published in The Tan Sheet
Executive Summary
PHENOLPHTHALEIN LINKED TO GREATER LYMPHOMA INCIDENCE IN TRANSGENIC MICE at high doses in new data presented April 30 by the National Toxicology Program/National Institute of Environmental Health Sciences to FDA's Carcinogenicity Assessment Committee at a meeting in Rockville, Md. After hearing the presentation on phenolphthalein, FDA's in-house cancer study review board voted in closed session on a number of questions regarding the safety of phenolphthalein. Following tabulation of the vote, the committee will provide recommendations to FDA's OTC division about the laxative ingredient.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning